Brown Advisory Inc. Cuts Stake in Edwards Lifesciences Corporation $EW

Brown Advisory Inc. lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,332,126 shares of the medical research company’s stock after selling 25,662 shares during the period. Edwards Lifesciences comprises 0.9% of Brown Advisory Inc.’s investment portfolio, making the stock its 27th biggest position. Brown Advisory Inc.’s holdings in Edwards Lifesciences were worth $625,064,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth about $266,000. NewEdge Advisors LLC boosted its position in Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after acquiring an additional 2,665 shares during the last quarter. Sei Investments Co. boosted its position in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after acquiring an additional 58,988 shares during the last quarter. Squarepoint Ops LLC boosted its position in Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after acquiring an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina boosted its position in Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after acquiring an additional 1,065 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,816,861.34. This represents a 2.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 81,038 shares of company stock valued at $6,683,255. 0.31% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on EW shares. Evercore restated an “outperform” rating and set a $93.00 price target on shares of Edwards Lifesciences in a research report on Friday, April 24th. Barclays reiterated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Wednesday, April 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Finally, BTIG Research boosted their target price on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $95.96.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $85.02 on Friday. The firm’s 50 day moving average price is $82.77 and its 200-day moving average price is $83.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $89.48. The firm has a market cap of $48.95 billion, a P/E ratio of 45.22, a P/E/G ratio of 2.13 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period in the prior year, the business posted $0.64 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.